Docetaxel plus prednisone as a first-line chemotherapy ... The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis ...

Experts developed consensus recommendations through the modified Delphi process for metastatic prostate cancer management ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

and a corticosteroid as a first-line therapy for metastatic castration-resistant prostate cancer (mCRPC). However, the panel agreed with the FDA reviewer’s position that the regimen had not yet ...

Men with metastatic castration-resistant prostate cancer (mCRPC ... use of drugs known to reduce ICI efficacy, such as steroids and antibiotics. "Considering the prevailing negativity of multiple ...